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Abstract:  Prostate   cancer   is   the   most   commonly   diagnosed   cancer   among   men   in   the  Western  9 
world.   Although   localised   disease   can   be   effectively   treated   with   established   surgical   and  10 
radiopharmaceutical   treatments   options,   the   prognosis   of   castration-­‐‑resistant   advanced   prostate  11 
cancer  is  still  disappointing.  The  objective  of  this  study  was  to  review  the  role  of  angiogenesis  in  12 
prostate   cancer,   and   to   investigate   the   effectiveness   of   anti-­‐‑angiogenic   therapies.   A   literature  13 
search   of   clinical   trials   testing   the   efficacy   of   anti-­‐‑angiogenic   therapy   in   prostate   cancer   was  14 
performed   using   Pubmed.   Surrogate   markers   of   angiogenic   activity   (microvessel   density   and  15 
VEGF-­‐‑A  expression)  were   found  to  be  associated  with   tumour  grade,  metastasis,  and  prognosis.  16 
Six   randomised   studies   were   included   in   this   review,   two   phase   II   trials   on   localised   and  17 
hormone-­‐‑sensitive  disease   (n=60   and  99  patients)  and   four  phase   III   trials   on   castration-­‐‑resistant  18 
refractory   disease   (n = 873   to   1224   patients).   Although   the   phase   II   trials   showed   improved  19 
relapse-­‐‑free   survival  and   stabilisation  of   the  disease,   the  phase   III   trials   found   increased   toxicity  20 
and   no   significant   improvement   in   overall   survival.  Although   angiogenesis   appears   to   have  an  21 
important   role   in   prostate   cancer,   the   results   of   anti-­‐‑angiogenic   therapy   in   castration-­‐‑resistant  22 
refractory  disease  have  hitherto  been  disappointing.  There   are  various  possible  explanations   for  23 
this  lack  of  efficacy  in  castration-­‐‑resistant  refractory  disease:  redundancy  of  angiogenic  pathways,  24 
molecular   heterogeneity   of   the   disease,   loss   of   tumour   suppressor   PTEN   expression   as  well   as  25 
various  VEGF-­‐‑A  splicing  isoforms  with  pro-­‐‑  and  anti-­‐‑angiogenic  activity.  A  better  understanding  26 
of   the   molecular   mechanisms   of   angiogenesis   may   help   to   develop   effective   anti-­‐‑angiogenic  27 
therapy  in  prostate  cancer.  28 
  29 
Keywords:  prostate  cancer,  angiogenesis,  VEGF-­‐‑A,  splicing  isoforms  30 
  31 
1.  Introduction  32 
Prostate  cancer  is  the  most  commonly  diagnosed  cancer  in  men  in  the  Western  world,  with  a  33 
median  age  at  diagnosis  of  66  years   [1].  There  will  be  an  estimated  160  000  new  cases  and  30  000  34 
deaths   in   2018   in   the   USA,   representing   19%   of   all   new   cancer   diagnoses   and   9%   of   all   cancer  35 
related   deaths,   respectively   [2].   In   the   United   Kingdom,   over   47   000   men   are   diagnosed   with  36 
prostate  cancer  every  year,  with  over  330  000  men  currently  living  with  the  disease  [3].  The  purpose  37 
of  this  literature  review  is  to  assess  whether  angiogenesis  is  important  in  prostate  cancer,  and,  if  so,  38 
whether  anti-­‐‑angiogenic  therapies  are  effective   in  the  treatment  of  prostate  cancer.  To  begin  with,  39 
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the  current  treatment  options  in  prostate  cancer  will  be  discussed,  along  with  a  summary  of  what  is  40 
already  known  in  relation  to  angiogenesis  in  cancer.  This  will  be  followed  by  the  literature  review  41 
on   angiogenesis   and   anti-­‐‑angiogenic   therapies   in   prostate   cancer   specifically,   and   finally   the  42 
discussion  will  consider  any  treatment  difficulties  that  have  emerged  in  such  studies.  43 
2.  Background  44 
2.1.  Prostate  cancer  45 
Prostate   cancer   is   characterised   by   slow   to  moderate  growth.  Consequently,  many   cases   are  46 
indolent,   and   in   up   to   70%   of   incidentally   diagnosed   cases   over   60   years   death   is   due   to   an  47 
unrelated  cause   [4].  The  5-­‐‑year  relative  survival  rate   for  men  diagnosed   in  the  USA  between  2001  48 
and  2007  with  local  or  regional  disease  was  100%,  whilst  the  rate  for  distant  disease  was  28.7%  [5].  49 
UK  statistics  show  similar  results:  5-­‐‑year  relative  survival  for  prostate  cancer  was  100%  in  localised  50 
disease   and  30%   in  distant  disease   for  patients  diagnosed  during  2002-­‐‑2006   in   the   former  Anglia  51 
Cancer  Network  [6].  Most  cases  of  prostate  cancer  are  diagnosed  by  prostate  specific  antigen  (PSA)  52 
testing,  or  rarely  by  rectal  examination.  Prostate  cancer  can  present  with  decreased  urinary  stream,  53 
urgency,  hesitancy,  nocturia,  or  incomplete  bladder  emptying,  but  these  symptoms  are  non-­‐‑specific  54 
and  are  infrequent  at  diagnosis  [7].  55 
2.2.  Treatment  options  in  prostate  cancer  56 
Prostate   cancer  staging   is  divided   into   four   stages.   Stage   1   and  2  cancers   are   localised   to   the  57 
prostate  whilst   stage   3   cancers   extend   into   the  periprostatic   tissue  or   the   seminal  vesicle,  without  58 
involvement  of  a  nearby  organ  or  lymph  node  and  with  no  distant  metastasis  [8].  Stage  4  tumours  59 
represent  those  that  have  spread  to  nearby  or  distant  organs  or  lymph  nodes  [8].  60 
Stage  1  tumours  and  stage  2  tumours  of  low  and  intermediate  risk  (Table  1.)  can  be  followed  61 
up   by   ‘watchful   waiting’   or   active   surveillance   and  monitoring   [9,   10].  Watchful   waiting   has   no  62 
curative  intent,  whilst  active  surveillance  and  monitoring  defers  treatment  with  curative  intent  to  a  63 
time  when  it  is  needed  [9].  Therefore,  in  active  surveillance  and  monitoring  therapy  is  reserved  for  64 
tumour  progression,  with  a  1-­‐‑10%  mortality  rate  [9].  65 
  66 









Low  risk   <10   and      ≤6   and      T1–T2a  
Intermediate  
risk  
10–20   or      7   or      T2b  
High  risk   >20   or      8–10   or      ≥T2c  
Table   1.   Risk   stratification   of   localised   prostate   cancer   according   to   NICE   guidance,   UK   [10].  67 
Gleason  score:  histological  pattern  of  the  tumour.  Stage  T1-­‐‑T2a:  tumour  involving  <50%  of  one  lobe.  68 
Stage  T2b:  tumour  involving  ≥50%  of  one  lobe.  Stage  T2c:  tumour  involving  both  lobes        69 
Radical   prostatectomy   is   a   treatment   option   for   localised   tumours   in   patients   with   few  70 
comorbidities.  Although  this  provides  an   improvement   in  disease  progression  compared  to  active  71 
surveillance  and  monitoring,   it  does  not   translate   into   a  statistical  difference   in  mortality:   10-­‐‑year  72 
cancer-­‐‑specific  survival  rates  were  98.8%  with  active  surveillance  and  monitoring  compared  to  99%  73 
with   radical  prostatectomy   [9].  Complications  of  radical  prostatectomy   include   the  mortality   and  74 
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morbidity   associated  with  major   surgery   and   anaesthesia,   penile   shortening,   impotence,   urinary  75 
and  faecal  incontinence,  and  inguinal  hernia  [8].  76 
Radiation  and  radiopharmaceutical  treatment  options  include  external-­‐‑beam  radiation  therapy  77 
[EBRT],  interstitial  implantation  of  radioisotopes  into  the  prostate  and  hormonal  manipulation  [9].  78 
EBRT   is   used   with   curative   intent   in   all   stages   of   prostate   cancer,   with   or   without   adjuvant  79 
hormonal   therapy.   Interstitial   implantation  of  radioisotopes   is  used   in  patient  with  stage   1   and  2  80 
tumours.  Short   term  results  are  similar  to   those  seen  with  EBRT  or  radical  prostatectomy,  but   the  81 
maintenance   of   sexual   potency   is   significantly   higher   (86-­‐‑96%)   when   compared   to   radical  82 
prostatectomy  or  EBRT  (10-­‐‑40%  and  40-­‐‑60%,  respectively)  [11].  83 
Hormonal   manipulation   options   include   surgical   castration   (orchidectomy)   or   medical  84 
castration  (LH-­‐‑RH  antagonists)  [12].  These  may  be  used  in  stage  3  or  4  cancers  and  can  be  enhanced  85 
by   the   addition   of   anti-­‐‑androgenic   therapy      and   adjuvant   treatment   with   bisphosphonates   [14].  86 
Recently   approved   anti-­‐‑androgen   agents   include   abiraterone   acetate,   an   inhibitor   of   cytochrome  87 
P450c17,   a   critical   enzyme   in   androgen   synthesis   and   enzalutamide,   a   second   generation  88 
androgen-­‐‑receptor–signaling  inhibitor  [13-­‐‑15].  89 
Treatment  options  for  high  stage  metastatic  hormone-­‐‑refractory  prostate  cancer  include  active  90 
cellular   immunotherapy   with   sipuleucel-­‐‑T.   which   has   resulted   in   increased   overall   survival   in  91 
metastatic   castration-­‐‑resistant   prostate   cancer,   in   a   double-­‐‑blind,   placebo-­‐‑controlled,   multicenter  92 
phase   3   trial   [16].   This   lead   to   its   approval   for   the   treatment   of   asymptomatic   or   minimally  93 
symptomatic   patients   with   nonvisceral   metastatic   castration-­‐‑resistant   prostate   cancer   in   2010.  94 
Radium-­‐‑223   dichloride   is   used   in   symptomatic   patients   with   bone   metastases   and   no   known  95 
visceral   metastases   [17].   Cabazitaxel,   a   derivative   of   docetaxel,   is   approved   as   a   second   line  96 
chemotherapy   agent   [18].   Further   possible   treatment  options   to   prevent   bone  metastases   include  97 
denosumab   (a   monoclonal   antibody   that   inhibits   osteoclast   function)   [19]   and   bone-­‐‑seeking  98 
radionucleotides  (strontium  chloride  Sr  89)  [20].     99 
Despite  a  widening  arsenal  of  new  treatment  options,  cure  is  rarely  achieved  in  stage  4  prostate  100 
cancer,   although   there   is   astriking   difference   in   treatment   response   between   individual   patients  101 
[21].   Such   outcomes   emphasize   the   need   for   research   into   further   treatment   options   in  102 
hormone-­‐‑refractory  advanced  prostate  cancer.  One  such  emerging   therapeutic  option   is   inhibition  103 
of  tumour-­‐‑related  angiogenesis.     104 
2.3.  Angiogenesis  in  cancer  105 
Angiogenesis   is  defined  as   the  development  of  new  vascular  vessels   from  pre-­‐‑existing  blood  106 
vessels.   It   has   a   critical   role   in   wound   healing   and   embryonic   development,   and   also   provides  107 
collateral   formation   for   improved   organ   perfusion   in   ischaemia   [22].   It   is   a   multi-­‐‑step   process  108 
triggered   by   an   angiogenic   stimulus   (Figure   1).  The   first   step   of   the   process   is   the   production   of  109 
proteases  which  degrade  the  basement  membrane.  This  is  followed  by  migration  and  proliferation  110 
of  the  endothelium,  resulting  in  the  formation  of  a  new  vascular  channel  [23].     111 
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  112 
Figure  1.  Angiogenesis  in  cancer.  Hypoxia  within  the  tumour  induces  the  release  of  pro-­‐‑angiogenic  113 
factors  and  results  in  degradation  of  the  basement  membrane  by  matrix  metalloproteinases  (MMP).  114 
The  endothelial  cells  start  to  differentiate  and  proliferate,  forming  new  blood  vessels.  The  newly  115 
formed  blood  vessels  allow  further  tumour  growth.  116 
Although  angiogenesis  is  not  entirely  necessary  for  tumour  initialisation  (some  tumours  of  the  117 
brain,  lung  and  liver  can  grow  along  pre-­‐‑existing  vessels)  [23],  once  a  tumour  reaches  a  size  of  more  118 
than  a  few  millimetres,  formation  of  new  blood  vessels  is  necessary  to  provide  an  appropriate  blood  119 
supply   to  support   tumour  cell  viability  and  proliferation.  Hence,  angiogenesis  plays  an   important  120 
role  in  tumour  progression,  and  is  now  recognised  as  one  of  the  hallmarks  of  cancer  [24].     121 
Angiogenesis   is   controlled   by   a   delicate   balance   between   angiogenesis   inducers   and  122 
angiogenesis   inhibitors.   In   a   growing   cancer   there   is   a   constant   production   of   angiogenesis  123 
inducers,   including   vascular   endothelial   growth   factor   (VEGF)-­‐‑A,   basic   fibroblast   growth   factor  124 
(bFGF,   also   known   as   FGF),   angiogenin,   tumour   necrosis   factor   (TNF)-­‐‑α,   granulocyte  125 
colony-­‐‑stimulating   factor   [G-­‐‑CSF],   platelet-­‐‑derived   endothelial   growth   factor   (PDGF),   placental  126 
growth   factor   (PGF),   transforming   growth   factor   (TGF)-­‐‑α,  TGF-­‐‑β,   interleukin-­‐‑8   (IL-­‐‑8),   hepatocyte  127 
growth   factor   (HGF),   and   epidermal   growth   factor   (EGF)   [22].   This   constant   production   of  128 
angiogenesis  inducers  results  in  increased  activity  of  endothelial  cells,  as  long  as  the  production  of  129 
anti-­‐‑angiogenic   factors   is   correspondingly   reduced   [25].   Among   the   angiogenesis   activators,  130 
VEGF-­‐‑A   and   bFGF   are   particularly   important   in   tumour   angiogenesis.   The   abundance   and  131 
redundant   activities   of  different   angiogenesis   inducers  may   explain   the   resistance   or   suboptimal  132 
effectiveness   of   anti-­‐‑angiogenic   therapies,   when   inhibitors   acting   only   on   a   single   angiogenesis  133 
activator  are  being  used  [25].  134 
Under   normal   conditions,   angiogenesis   inducers   are   balanced   by   naturally   occurring  135 
angiogenesis   inhibitors,   such  as   endostatin,  angiostatin,   IL-­‐‑1,   IL-­‐‑12,   interferons,  metalloproteinase  136 
inhibitors,  and  retinoic  acid  [25,26].  These  inhibitors  can  either  disrupt  new  vessel  formation  or  can  137 
help   to   remove   already   formed   vascular   channels.   Shifting   the   balance   towards   angiogenesis  138 
inhibition   can   interfere   with   important   physiological   roles   of   angiogenesis,   such   as   in   embryo  139 
development,  wound  healing,  and  renal  function.  Interference  with  wound  healing  is  a  particularly  140 
important  concern  in  cancer  treatment,  for  example  resulting  in  delayed  post-­‐‑operative  healing  [27].  141 
Another   example   involves   the   inhibition   of   VEGF-­‐‑A,   resulting   in   vasoconstriction   by   means   of  142 
elevated  NO   production,   consequently   elevating   blood   pressure   [28],   and   increasing   the   risk   of  143 
thrombogenesis,  resulting  in  stroke  or  myocardial  infarction.  These  factors  can  potentially  limit  the  144 
use  of  angiogenesis  inhibition  in  cancer,  on  account  of  their  potential  side  effects.  145 
2.4.  Angiogenesis  inhibition  in  cancer  146 
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Although  angiogenesis   is   an   essential   factor   in   tumour  progression,   by  means  of  new  vessel  147 
formation,   this   also   means   that   angiogenesis   inhibition   may   only   result   in   inhibition   of   further  148 
tumour   growth   and   may   not   actively   eliminate   the   tumour.   This,   and   the   redundancy   of   the  149 
numerous   angiogenesis   inducers   as   listed   above,   explain   why   the   utilisation   of   angiogenesis  150 
inhibitors   as   a  monotherapy   has   not   proved   to   be   as   effective   as   initially   expected   [29].      Hence,  151 
angiogenesis   inhibitor   therapeutic   regimes  may   require   a   combination   of   several   anti-­‐‑angiogenic  152 
strategies   or  may   need   to   be   complemented   by   other   non-­‐‑angiogenesis   related   chemotherapeutic  153 
agents  in  order  to  achieve  an  optimal  therapeutic  effect  [30].  154 
Based  on  the  target  of   the  therapeutic  agent,  angiogenesis   inhibition  can  be  divided   into   two  155 
main  groups:  direct  and   indirect   inhibition   [31].  Direct   inhibitors   target  growing  endothelial  cells,  156 
whilst   indirect   inhibitors   target   the   tumour   cells   or   tumour-­‐‑associated   stromal   cells.   Small  157 
molecular   fragments   (for   example,   arrestin,   tumstatin,   canstatin,   endostatin,   and   angiostatin)   are  158 
the  products  of  proteolytic  degradation  of   the   extracellular  matrix,  and  act   as  direct   inhibitors  by  159 
means  of  inhibition  of  the  endothelial  cell  proliferation  and  migration  induced  by  VEGF-­‐‑A,  bFGF,  160 
PDGF,   and   interleukins   [32].   The   direct   anti-­‐‑angiogenic   effect   of   targeting   integrins   (cellular  161 
adhesion   receptors),   has   also   been   demonstrated   [32],   and   an   integrin   inhibitor,   cilentigide,   has  162 
been  shown  to   inhibit   tumour  cell   invasion  [33].  Unfortunately,  even  though  cilentigide  acts  both  163 
on   tumour   cells   and   endothelial   cells   and   could   be   a   prime   example   of  multifactorial   treatment,  164 
results  of  clinical  trials  have  proved  disappointing  so  far  [34].     165 
The   most   extensively   clinically   used   direct   anti-­‐‑angiogenic   strategy   targets   VEGF-­‐‑A   or   its  166 
receptors.  VEGF-­‐‑A  binds   to   its   receptors   to   stimulate   the  proliferation  of   endothelial  cells  via   the  167 
RAS–RAF–MAPK   (mitogen-­‐‑activated   protein   kinase)   signalling   pathway   [35].   Bevacizumab   is   a  168 
humanised  IgG1  monoclonal  antibody  against  VEGF-­‐‑A.  It  selectively  binds  to  circulating  VEGF-­‐‑A,  169 
preventing   its   interaction   with   its   receptor,   VEGF-­‐‑receptor   2,   expressed   on   the   surface   of  170 
endothelial   cells.   Initial   studies   showed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            171 
clinical  improvement  when  bevacizumab  was  used  in  combination  with  chemotherapy  in  a  number  172 
of  cancers,  without  a  marked  increase  in  toxicity  [36].  Subsequently  it  has  been  approved  as  part  of  173 
a   combination   therapy   in   the   treatment   of   various   cancers,   including  metastatic   lung,   colorectal,  174 
and   renal   cell   carcinoma,   and   as   a   single   agent   treatment   in   adult   glioblastoma   [37].   However,  175 
subsequent  studies  have  revealed  adverse  effects,  including  gastrointestinal  perforation,  nephrotic  176 
syndrome,  thromboembolism,  surgical  wound  healing  complications  and  hypertension  [37,38].  177 
In  contrast,   indirect  angiogenesis   inhibition   involves  an   interplay  between  tumour  or  stromal  178 
cells   and  angiogenesis.  One   example   involves   the   inhibition   of   epidermal   growth   factor   receptor  179 
(EGFR),   a   tyrosine   kinase   receptor.   Tumour   cell   expression   and   activation   of   EGFR   induces  180 
interleukin   production,   which   is   demonstrated   to   promote   intratumoural   angiogenesis.   Thus,  181 
blocking   the   expression   and/or   activity   of   EGFR   can   result   in   indirect   inhibition   of   angiogenesis  182 
[39].  183 
To   summarise,   a   number   of   anti-­‐‑angiogenesis   drugs   have   already   been   approved   and   are  184 
currently  used  in  cancer  treatment.  This  prompts  the  question  whether  angiogenesis  plays  any  role  185 
in   prostate   cancer   progression,   and,   if   so,  whether   anti-­‐‑angiogenic   therapy  would   be   effective   in  186 
refractory  castration-­‐‑resistant  prostate  cancer,  for  which  the  current  treatment  options  are  limited.     187 
3.  Results  188 
3.1.  Angiogenesis  in  prostate  cancer  189 
Currently  there  are  no  direct  markers  to  assess  angiogenic  activity  in  prostate  cancer,  but  it  is  190 
reasonable   to   assume   that   vascular   density   is   an   indicator   of   intratumoural   angiogenic   activity.     191 
Microvessel  density   [MVD]   is  considered  a  good  surrogate  marker  of  angiogenic  activity  and  has  192 
been  demonstrated  as  a  prognostic  factor  in  various  tumours,  including  breast  and  colon  cancers  as  193 
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well   as   malignant   melanoma   [40].   MVD   can   be   assessed   by   histological   examination   of   the  194 
vasculature,  either  by  assessing  the  most  vascularised  area  of  the  tumour  (‘hot  spot’)  or  a  random  195 
representative  area.  Preliminary  data  suggested  that  MVD  is  associated  with  higher  tumour  grade  196 
and   stage,   and   worse   outcome   in   prostate   cancer   [41,42].   Also,   ultrasound   imaging   studies   of  197 
haemodynamic   indices   have   shown   a   higher   peak   intensity   in   high-­‐‑grade   tumours   [43].   Later  198 
studies,  however  have  failed  to  confirm  that  MVD  is  an  independent  prognostic  factor  in  untreated  199 
tumours,   and   no   correlation   has   yet   been   established   between   MVD   and   effectiveness   of  200 
anti-­‐‑angiogenic   treatment   in   prostate   cancer   [44].   Reasons   for   these   conflicting   results   potentially  201 
include   different   counting   methods,   diferences   in   antibodies   used,   different   population   sizes,  202 
personal   experience   and   pathological   background   [45].   A   further   limiting   factor   is   the   complex  203 
geometrical  structure  of  the  newly  fromed  vascular  system,  which   is  difficult  to  analyse  on  a  two  204 
dimensional  histological  section  [46].  Fractal  geometry  to  estimate  the  surface  dimension,  computer  205 
aided  automated   image  analysis,   3D  models  or  magnetic  resonance   imaging   could  potentially  be  206 
used  to  overcome  these  shortcomings,  [46,47].  207 
Another  possible  surrogate  marker  for  tumour  angiogenesis  is  by  an  assessment  of  the  level  of  208 
angiogenic   regulators   in   the   tumour.   Both   physiological   and   pathological   angiogenesis   is  209 
predominantly   regulated   by   VEGF,   which   has   various   protein   isoforms,   each   acting   on   their  210 
specific   tyrosine  kinase  receptor   at   the   cell   surface   [48].  Among  the  VEGF   isoforms,  VEGF-­‐‑A  has  211 
been  extensively  studied,  and  it  has  been  demonstrated  to  play  an  important  role  in  prostate  cancer  212 
angiogenesis  [49].  In  addition,  VEGF-­‐‑A  has  been  found  to  be  overexpressed  in  prostate  cancer,  and  213 
a   high   level   of   VEGF-­‐‑A   is   associated   with   distant   metastasis   and   a   poorer   prognosis   [50-­‐‑52].  214 
Furthermore,   in   prostate   cancer   a   high-­‐‑level   VEGF-­‐‑A   expression   has   been   found   not   only   in  215 
endothelial  cells,  but  also  in  tumour  cells  [53].     216 
These   findings   suggest   that   angiogenesis   is   important   in   prostate   cancer,   prompting  217 
subsequent  clinical  studies  to  assess  whether  anti-­‐‑angiogenesis  therapy  is  effective  in  the  treatment  218 
of  prostate  cancer.  219 
3.2.  Anti-­‐‑angiogenesis  clinical  studies  in  prostate  cancer  220 
An   unfiltered   Pubmed   search   for   the   keywords   “angiogenesis”   and   “prostate”   revealed   a  221 
steady   increase   in  published  papers  between  2000   and  2013   (from  70  per  year   in   2000   to   213  per  222 
year  in  2013)  followed  by  a  slow  decline  (down  to  115  in  2018).  This  appears  to  reflect  the  fact  that,  223 
despite   the   promising   findings   of   initial   studies,   suggesting   an   important   role   of   angiogenesis   in  224 
prostate  cancer,  phase  III  clinical  trials,  mainly  conducted  after  2010,  have  proved  disappointing  so  225 
far.     226 
Since  VEGF-­‐‑A  was  demonstrated  to  be  overexpressed   in  prostate  cancer  and  associated  with  227 
poor   prognosis   and   metastasis,   most   anti-­‐‑angiogenic   clinical   studies   in   prostate   cancer   have  228 
targeted   VEGF-­‐‑A.   A   randomised   phase   II   trial   on   bevacizumab   involving   99   patients   with  229 
hormone-­‐‑sensitive  prostate  cancer  showed  improved  relapse-­‐‑free  survival  when  bevacizumab  was  230 
used   alongside   hormone-­‐‑deprivation   therapy   (Table   2)   [54].   A   randomized,   double-­‐‑blind,  231 
placebo-­‐‑controlled   phase   III   clinical   study   of   1050   patients   with   prostate   cancer   showed   some  232 
improvement   in   progression-­‐‑free   survival,   but   found   no   significant   improvement   in   overall  233 
survival   in  metastatic,   castration-­‐‑resistant   prostate   cancer,  when   bevacizumab  was   used   together  234 
with  docetaxel   chemotherapy   and   prednisone   hormonal   therapy   [55].   Furthermore,   bevacizumab  235 
resulted  in  increased  toxicity  and  a  greater  incidence  of  treatment-­‐‑related  deaths  [55].  This  suggests  236 
that   bevacizumab   has   some   positive   effect,   especially   on   hormone-­‐‑sensitive   recurrent   prostate  237 
cancer,   but   in  hormone-­‐‑resistant  refractory   tumours,   in  which   the  conventional   treatment  options  238 
are  particularly  prone  to  failure,  adding  bevacizumab  treatment  does  not  have  any  clinical  benefit  239 
(Table  2).  240 
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Aflibercept  (a  hybrid  protein  composed  of  various  domains  of  VEGF-­‐‑receptors  1  and  2,  fused  241 
to  human  immunoglobulin  G1)  also  targets  the  VEGF-­‐‑A  pathway,  by  acting  as  a  decoy  receptor  for  242 
VEGF-­‐‑A.   Unfortunately,   similar   to   bevacizumab,   in   a   phase   III   multicentre,   randomised  243 
double-­‐‑blind   placebo-­‐‑controlled   parallel   group   study   in   1224   men   with   castration-­‐‑resistant  244 
refractory   tumours,   aflibercept   therapy   combined   with   docetaxel   chemotherapy   and   hormonal  245 
therapy  did  not  show  any  improvement  in  overall  survival  [56].     246 
Sunitinib   and   cediranib   are   small   multireceptor   molecule   tyrosine   kinase   inhibitors,   with   a  247 
demonstrated  activity  against  VEGF-­‐‑receptors  1  and  2.  Sunitininb  is  approved  for  the  treatment  of  248 
gastrointestinal   stromal   tumour,   renal   cell   carcinoma   and   pancreatic   neuroendocrine   tumours.  249 
However,   in   a  randomised,  placebo-­‐‑controlled,  phase   III   trial   of  sunitinib   therapy   combined  with  250 
hormonal  therapy  in  873  patients  with  refractory  castration-­‐‑resistant  prostate  cancer,  there  was  no  251 
improvement  in  overall  survival  compared  to  placebo  [57].  252 
Furthermore,   these   anti-­‐‑VEGF-­‐‑A   therapies   have   been   associated   with   an   increased   rate   of  253 
toxicity  and  adverse  effects,  resulting  in  discontinuation  of  treatment  (27%  vs  7%)  [57].  These  toxic  254 
and   adverse   effects   included   fatigue,   asthenia,   hand-­‐‑foot   syndrome,   hypertension,   bowel  255 
perforation,  pulmonary   thromboembolism,  and  gastrointestinal  bleeding,  seen   in  both  pre-­‐‑clinical  256 
and  clinical  studies  [58,  59].  In  addition,  treatment-­‐‑related  haematological  problems  also  emerged  in  257 
up  to  20%  of  the  patients,  including  lymphopenia,  neutropenia,  and  anaemia  [57].  258 
Thalidomide   is   an   immune-­‐‑modulatory   drug,   which   also   has   anti-­‐‑angiogenic   effects.  259 
Lenalidomide   is   a   more   potent   analogue   of   thalidomide,   with   less   prominent   side   effects.   The  260 
mechanism  of  the  anti-­‐‑angiogenic  effect  of  lenalidomide  is  not  entirely  elucidated,  but  appears  to  be  261 
through   multiple   mechanisms,   including   inhibition   of   VEGF-­‐‑induced  262 
phosphatidylinositol-­‐‑3,4,5-­‐‑trisphosphate  (PI3K)-­‐‑Akt  pathway  signalling  [60].  Lenalidomide  therapy  263 
in  non-­‐‑metastatic  prostate  cancer   in   a  phase   I/II  double-­‐‑blinded,  randomized  study  of   60  patients  264 
resulted   in   stabilisation   of   the   disease   and   a   decline   in   PSA,   with   minimal   toxicity   [61].   A  265 
randomised,   double-­‐‑blind,   placebo-­‐‑controlled   phase   III   trial   in   1059   patients   with  266 
castration-­‐‑resistant   refractory   prostate   cancer,   however   showed   worse   overall   survival   when  267 
lenalidomide  was  added  to  prednisone,  hormonal,  and  docetaxel  chemotherapy,  compared  to  the  268 
placebo   group   [62].   There   was   also   a   25%   increase   in   adverse   events,   which   included  269 
haematological  side  effects  (34%  vs  20%),  diarrhoea  (7%  vs  2%),  pulmonary  embolism  (6%  vs  1%),  270 
and  asthenia  (5%  vs  3%)  [62].  271 
  272 
Drug   Mechanism   of  
action  













II   99   Improved  
relapse-­‐‑free  
survival  [54]  




Aflibercept   Binds  to  circulating  
VEGF-­‐‑A  
III   1224   No  
improvement  




Sunitinib   Receptor  tyrosine  
kinase  inhibitor     














III   1059   Worse  overall  
survival  [62]  
Table  2.  Anti-­‐‑angiogenesis  clinical  studies  in  treatment  of  prostate  cancer  273 
To  summarise,  these  findings  suggest  that  anti-­‐‑angiogenic  therapy  has  no  clinical  benefit  when  274 
added  to  chemotherapy  or  hormonal  therapy  in  refractory,  castration-­‐‑resistant  prostate  cancer.  275 
4.  Discussion  276 
Clinical   trials   which   showed   an   association   between   high   VEGF-­‐‑A   expression   and   tumour  277 
progression  assessed  VEGF-­‐‑A  protein  levels  by  immunohistochemistry,  ELISA  methods  or  mRNA  278 
levels   by   reverse-­‐‑transcription-­‐‑polymerase   chain   reaction   (RT-­‐‑PCR).   Despite   high   VEGF-­‐‑A  279 
expression   in   advanced   prostate   cancer   using   these  methods,   anti-­‐‑angiogenic   therapies   targeting  280 
the  VEGF-­‐‑A  pathway  have  failed  to  provide  significant  treatment  benefits  [63,64].  There  are  various  281 
possible   explanations   for  resistance   to   anti-­‐‑angiogenic   therapy   in  prostate  cancer.  Redundancy  of  282 
angiogenic   pathways   means   that   targeting   a   single   pathway   may   result   in   upregulation   of  283 
alternative  pathways.  For  example,  with  long-­‐‑term  bevacizumab  treatment,  which  blocks  VEGF-­‐‑A,  284 
there   is  upregulation  of  EGF,  HGF  and  PDGF  [65].  Lindholm  et   al  demonstrated   in  breast  cancer  285 
xenografts   that   targeting   these   pathways   can   be   effective   in   anti-­‐‑angiogenic   therapy   [66].   A  286 
combination   of   different   anti-­‐‑angiogenic   therapies   in   prostate   cancer   has   also   showed   some  287 
promising  results:  a  phase  II  study  of  combined  bevacizumab  and  lenalidomide  therapy,  added  to  288 
docetaxel   and   prednisone   chemotherapy   and   hormonal   therapy   in   63   patients   with   metastatic  289 
castration-­‐‑resistant   prostate   cancer   found   that   combined   anti-­‐‑angiogenic   therapy   can   be   safely  290 
administered,  but  further  randomised  trials  are  required  to  confirm  clinical  benefit  [67].  291 
Another  reason  for  treatment  resistance  is  due  to  the  fact  that  prostate  cancer  is  a  molecularly  292 
heterogeneous  disease,  and  there  is  currently  a  lack  of  biomarkers  that  can  help  select  those  patients  293 
who  are  likely  to  benefit  from  anti-­‐‑angiogenic  therapy  or  that  can  assess  response  to  anti-­‐‑angiogenic  294 
treatment   [48].   The   genetic   signature   of   the   VEGF-­‐‑A   pathway   or   variations   in   VEGF-­‐‑A   or   its  295 
receptors   could   be   possible  markers   to   predict   therapy   response,   but   these   have   as   yet   not   been  296 
validated  [68,69].  It  is  hoped  that  further  stage  III  trials  will  be  able  to  identify  subgroups  of  patients  297 
who  could  benefit  from  anti-­‐‑angiogenic  treatment.  298 
Resistance  to  sunitinib  tyrosine-­‐‑kinase-­‐‑inhibitor  has  been  shown  to  be  associated  with   loss  of  299 
the   tumour   suppressor   protein   phosphatase   and   tensin   homolog   [PTEN].   PTEN   is   a   gatekeeper  300 
protein   that   negatively   regulates   intracellular   levels   of   PI3K   and   consequently   suppresses   the  301 
PI3K-­‐‑Akt   pathway,   which   normally   promotes   cell   survival   and   growth   [70].   Reinstating   PTEN  302 
activity,   by   suppression   of   the   PI3K-­‐‑Akt   pathway   in   in   vitro   studies,   has   been   shown   to   restore  303 
sensitivity   to   sunitinib   in   cancer   cells   [70].   Loss   of   PTEN   activity   is   considered   a   key   event   in  304 
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prostate  carcinogenesis,  and  reinstating  PTEN  activity   in  prostate  cancer  seems  to  be  a  promising  308 
tool  in  overcoming  sunitinib  resistance.  In  addition,  activation  of  the  PI3K-­‐‑Akt  pathway  in  tumours  309 
with  PTEN  deletion  has  been  shown  to  be  associated  with  repressed  androgen  signalling  in  prostate  310 
cancer,   while   suppression   of   the   PI3K-­‐‑Akt   pathway   was   demonstrated   to   activate   androgen  311 
receptor   signalling   [71,72].   In   a   similar   way,   suppression   of   the   androgen   signaling   pathway  312 
resulted  in  activation  of  the  PI3K-­‐‑Akt  pathway  [71].  This  suggests  that  there  is  a  cross-­‐‑talk  between  313 
the   androgen   receptor   and   PI3K-­‐‑Akt   pathways,   which   would   at   least   in   part   explain   the  314 
castration-­‐‑resistant   phenotype   observed   in   tumours   with   PTEN   deletion.   Since   activation   of   the  315 
PI3-­‐‑Akt   pathway   appears   to   play   an   important   role   in   resistance   to   both   sunatininb   and  316 
anti-­‐‑androgenic  therapy,  suppression  of  the  PI3K-­‐‑Akt  pathway  could  help  overcome  difficulties  in  317 
anti-­‐‑angiogenic   and   anti-­‐‑androgenic   therapy.   Recent   preclinical   studies   on   mouse   models   have  318 
shown   that   targeted   inhibition   of   the   PI3K-­‐‑Akt   pathway   in   castration-­‐‑resistant   prostate   cancer  319 
resulted   in   both   inhibited   cancer   cell   proliferation   and   MVD   [73,74].   Suboptimal   results   with  320 
bevacizumab   treatment   may   also   relate   to   the   interaction   between   the   androgen   receptor   (AR)  321 
signalling   and   angiogenic   pathways.   It   has   been   long   established   that   androgens   upregulate  322 
VEGF-­‐‑A   expression   [75],   although   the   mechanism   of   this   is   not   entirely   understood   [76].   Most  323 
recently,   an   interaction   between   epigenetic   factors   (Lysine   specific  demethylase  1   (LSD1),  protein  324 
arginine  methyltransferase  5  (PRMT5))  [77,78],  zinc-­‐‑finger  transcription  factors  (specificity  protein  1  325 
(Sp1),  Wilms  tumor  gene  1  (WT1)  early  growth  factor  1  (EGR1))  [76,79],  different  AR  splice  variants  326 
[80]   and   hypoxia  mediated   by   the   hypoxia-­‐‑inducable   factor   1   α   (HIF-­‐‑1α)   [81]   have   emerged   as  327 
potential   mechanisms   for   androgen-­‐‑dependent   VEGF-­‐‑A   regulation.   Furthermore,   AR   has   been  328 
shown  to  regulate  EGFR  expression  in  prostate  cancer  cells.  [82,  83]  In  addition  to  the  role  of  EGFR  329 
in   indirect   angiogenesis   promotion   through   interleukin   production,   [39]   it   has   also   been  330 
demonstrated  to  upregulate  VEGF-­‐‑A  directly  and  through  induction  of  HIF-­‐‑1α.  [84,  85]  (Figure  2)  331 
The   interaction   and   the   importance   of   angiogenesis   and   hormonal   therapy   in   tumour  332 
progression   have   initiated   a   clinical   trial   implementing   dual   targeting   of   angiogenesis   and  333 
androgen   signalling   in  hormone-­‐‑sensitive   tumours   [54].  As  discussed  above,   this  phase   II  clinical  334 
trial   ,  which   combined   short-­‐‑course   androgen   deprivation   therapy  with   bevacizumab,   improved  335 
relapse   free   survival   in   recurrent,   hormone-­‐‑sensitive   tumours.   In   addition,   it   has   been  336 
demonstrated   that   androgen  deprivation   by   castration,   causes   hypoxia   in   prostatic   tumour   cells.  337 
[86,87]  Hypoxia  consequently  enhances  the  transcriptional  activity  of  AR  in  prostatic  tumour  cells  338 
at   low   androgen   levels,   such   as   seen   in   castration-­‐‑resistant   prostate   cancer.   [88]   It   has   been  339 
suggested  that  the  activation  of  AR  in  hypoxic  conditions  is  HIF-­‐‑1α  mediated,  [89]  hence  targeting  340 
HIF-­‐‑1α  could  influence  the  AR  stimulatory  effect  of  hypoxia  in  castration-­‐‑resistant  prostate  cancer.  341 
Recently,   dual   targeting   of  HIF-­‐‑1α   and  AR   pathways   by  HIF-­‐‑1α   inhibitors   and   enzalutamide,   a  342 
second  generation  AR  inhibitor,  showed  synergistic  effect  in  castration-­‐‑resistant  prostate  cancer  cell  343 
lines,   also   resulting   in  decreased  VEGF-­‐‑A   levels   [81].   In   addition,   suppression   of   Sp1   binding   to  344 
VEGF-­‐‑A  promoter  resulted  in  significant  reduction  of  VEGF-­‐‑A  level  in  castration-­‐‑resistant  prostate  345 
cancer   cells   [79].   However,   a   better   understanding   of   the  mechanism   of   the   interaction   between  346 
VEGF-­‐‑A   and  AR   is   still   needed   to   identify   those   patients   who  may   benefit   from  dual   targeting  347 
therapy.  [79,  90]  348 
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350 
Figure  2.  Interaction  between  angiogenic  and  androgen  receptor  pathways  in  prostate  cancer  cells.  351 
Castration   results   in   androgen   depletion   which   causes   hypoxia   Hypoxia   enhances   the  352 
transcriptional   activity      of   AR   at   low   androgen   levels,   as   seen   in   castration-­‐‑resistant   prostate  353 
cancer.  The  activated  androgen  receptor  promotes   the  overexpression  of  VEGF-­‐‑A  through  HIF-­‐‑1α  354 
and   Sp1   related   mechanisms   and   also   via   regulation   of   EGFR   expression   and   upregulation   of  355 
cytokins,  mainly  interleukin  (IL)  -­‐‑  6.  [90]     356 
Targeting  VEGF-­‐‑A  also  raises  a   further  question:  does   inhibition  of  VEGF-­‐‑A   result   in   a  pure  357 
anti-­‐‑angiogenetic  effect?  Interestingly,  it  has  been  shown  that  VEGF-­‐‑A  has  different  splice  isoforms,  358 
and  these  different  isoforms  can  show  pro-­‐‑  or  anti-­‐‑angiogenic  functions.  [91]  In  the  terminal  exon  of  359 
the  VEGF-­‐‑A  gene,  there  are  two  alternative  splice  sites.  Splicing  at  the  proximal  splice  site  results  in  360 
the  canonical  angiogenic  VEGF165a  isoform.  Splicing  at  the  distal  splice  site  results  in  an  alternative  361 
splicing   isoform   VEGF165b,   which   has   been   found   to   have   anti-­‐‑angiogenic   effect   by   inhibiting  362 
vasodilation   and   reducing   permeability   [92,   93].   The   level   of   the   anti-­‐‑angiogenic   VEGF165b   splice  363 
variant  has   also  been   found   to  be  decreased   in   cancer   cells,   compared   to  normal   tissue   cells.   [93]  364 
This  means   that,   in   cancer   cells,   there   appears   to   be   a   shift   towards   the   pro-­‐‑angiogenic  VEGF165a  365 
splice  variant  at   the  expense  of   the  anti-­‐‑angiogenic  VEGF165b  splice  variant.  The  cause  of  this  shift  366 
has  not  been   entirely   elucidated,   but  nuclear   receptor-­‐‑coregulator  complexes  have  been   shown   to  367 
regulate  splicing  events,   therefore  aberrant  recruitment  of  nuclear  receptor-­‐‑coregulator  complexes  368 
to  the  VEGF  promoter   to  promote  VEGF165a  splicing  has  been  suggested  as  a  possible  explanation  369 
[48,94].   Current   anti-­‐‑VEGF-­‐‑A   therapies   lack   isoform   specificity,   as   the   epitope   of   bevacizumab  370 
binds  the  N-­‐‑terminal  region  of  VEGF-­‐‑A,  which   is  present   in  all   splice   isoforms  [95].  Thus,  current  371 
anti-­‐‑angiogenic  therapies  targeting  VEGF-­‐‑A  function  may  result   in  both   inhibition  and  promotion  372 
of   tumour   angiogenesis.  However,   the   fact   that   the   two   isoforms  appear   to   have   different   splice  373 
sites   and   post-­‐‑translational   regulation,   offers   the   possibility   of   selectively   targeting   specific  374 
isoforms.   Serine-­‐‑arginine   protein   kinase   1   (SRPK1),   a   kinase   that   phosphorylates   SR-­‐‑protein,  375 
appears  to  stimulate  VEGF165a  splicing,  whilst  VEGF165b  splicing  has  been  shown  to  be  stimulated  by  376 
Clk1/4,   a  dual   specific   protein   kinase   [96-­‐‑98].   Investigation  with   SRPK1   knocked-­‐‑down   cell   lines  377 
showed  a  shift  towards   the  anti-­‐‑angiogenic  VEGF165b   isoform,  while  xenografts  showed  decreased  378 
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tumour  growth  and  decreased  MVD  in  tumours  [99].  In  addition,  specific  inhibition  of  SRPK1  in  a  386 
mouse  tumour  model  has  been  shown  to  be  associated  with  reduced  tumour  growth  [100].  (Figure  387 
3)  388 
  389 
Figure  3.  Alternative  splicing  of  VEGF-­‐‑A.  Splicing  at  the  proximal  splicing  site  (PSS)  is  stimulated  390 
by  SRPK1  and  results  in  the  pro-­‐‑angiogenic  VEGF165a  splice  variant.  Clk1/4  stimulates  splicing  at  the  391 
distal  splicing  site  (DSS),  which  results  in  the  anti-­‐‑angiogenic  VEGF165b  isoform.  392 
Most   current   mainstream   anti-­‐‑angiogenic   treatment   therapies   focus   on   direct   angiogenesis  393 
inhibition.  A   further  possible   treatment  option   is   indirect   inhibition  of   angiogenesis,   targeting  an  394 
interplay  between  tumour  or  stromal  cells  and  angiogenesis.  The  galectin   family  of  proteins  have  395 
emerged  as  playing  an   important  role   in   this   interplay,   facilitating   tumour  progression.  Galectins  396 
are   β-­‐‑galactoside-­‐‑binding   lectin   proteins,   which   are   overexpressed   in   various   cancers   and   have  397 
been  associated  with  poor  prognosis  and  tumour  progression  in  prostate  cancer  [101].  In  addition  to  398 
their  intracellular  function  of  promoting  cell  transformation  and  survival,  galectins  are  also  secreted  399 
into  the  extracellular  space.  Here  they  interact  with  cell  surface  receptors,  resulting  in  suppression  400 
of   the   immune   response   and   promotion   of   angiogenesis,   likely   by   means   of   interaction   with  401 
VEGF-­‐‑receptor2   [102,103].   Rabinovich   and   colleagues   identified   that   prostate   cancer   shows   a  402 
unique   galectin   expression   profile   during   cancer   progression,   and   showed   that   galectin-­‐‑1   is  403 
uniquely   expressed   at   high   levels   in   advanced   prostate   cancer   [104].   This   makes   galectin-­‐‑1   a  404 
potential  target  of  angiogenesis  therapy  in  advanced  prostate  cancer  [105].  405 
  406 
5.  Materials  and  Methods     407 
The  literature  review  was  conducted  by  a  Pubmed  literature  search  engine  using  a  collection  of  408 
keywords   with   no   restriction   on   publication   date.   The   following   word   strings   were   used   as  409 
keywords:   “angiogenesis”[All   Fields]]   AND   [“prostatic   neoplasms”[MeSH   Terms]   OR  410 
[“prostatic”[All   Fields]   AND   “neoplasms”[All   Fields]]   OR   “prostatic   neoplasms”[All   Fields]   OR  411 
[“prostate”[All   Fields]   AND   “cancer”[All   Fields]]   OR   “prostate   cancer”[All   Fields].   The   search  412 
results   were   subsequently   filtered   by   article   type,   specifically   clinical   trials   and   review   articles.  413 
Abstracts  were  assessed  for  relevance  with  subsequent  review  of  full  text  versions.  Only  phase  II  or  414 
III   studies  were   included.   Studies   cited  by   these   articles,   but  not   included   in   the   algorithm,  were  415 
also  manually  scoped  and  were  also  subject  of  the  review.     416 
6.  Conclusions  417 
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The   association   of  MVD   and   overexpression   of   VEGF-­‐‑A  with   tumour   prognosis   in   prostate  418 
cancer   suggested   that   angiogenesis   has   an   important   role   in   prostate   cancer   progression.  419 
Supplementation  of  hormonal  manipulation  and  chemotherapy  with  anti-­‐‑angiogenesis   therapy   in  420 
hormone-­‐‑sensitive  prostate  cancer  showed  some  positive  effect,   further  supporting  the  hypothesis  421 
that  angiogenesis  is  an  important  factor  in  prostate  cancer.  Despite  this,  clinical  trials  in  refractory  422 
castration-­‐‑resistant  prostate  cancer  hitherto  have  shown  increased  toxicity  with  no  clinical  benefit.  423 
A  better   understanding  of   the  mechanism   of   angiogenesis  may   help   to   understand   the   failure  of  424 
trials,  possibly  leading  to  targeted  anti-­‐‑angiogenic  therapies  in  prostate  cancer.  These  could  include  425 
identification   of   specific   subgroups   of   patients   who   might   benefit   from   therapies,   targeting  426 
tumour-­‐‑suppressor  genes  that  play  a  role  in  treatment  resistance,  or  by  identifying  and  selectively  427 
targeting  splice  variants  of  VEGF-­‐‑A.  428 
Funding:   Funding   for   this   study   was   supported   by   grants   from   British   Heart   Foundation   to   SO  429 
(PG/15/53/31371),  Diabetes  UK  to  SO  (17/0005668).  430 
Acknowledgments:  We  wish  to  acknowledge  Cornelia  Szecsei  for  critical  reading  of  the  manuscript.     431 
Conflicts  of  Interest:  The  authors  declare  no  conflict  of  interest  432 
References  433 
1.   National   Cancer   Institute:   SEER   Stat   Fact   Sheets:   Prostate.   Bethesda,   MD:   National   Cancer  434 
Institute.  Available   from.https://seer.cancer.gov/statfacts/html/prost.html#prevalence   [Accessed   10th  435 
March  2018]  436 
2.   American   Cancer   Society:   Cancer   Facts   and   Figures   2018.   Atlanta,   Ga:   American   Cancer   Society,  437 
2018.  Available   from.  438 
https://www.cancer.org/content/dam/cancer-­‐‑org/research/cancer-­‐‑facts-­‐‑and-­‐‑statistics/annual-­‐‑cancer-­‐‑facts-­‐‑439 
and-­‐‑figures/2018/cancer-­‐‑facts-­‐‑and-­‐‑figures-­‐‑2018.pdf  [Accessed  10th  March  2018]  440 
3.   Cancer   Research   UK.   Prostate   cancer   incidence   statistics   [Internet].   2014   Available   from:  441 
http://www.cancerresearchuk.org/cancer-­‐‑info/cancerstats/types/prostate/incidence/#age   [Accessed   14th  442 
August  2018]  443 
4.   Zlotta  AR,  Egawa  S,  Pushkar  D,  et  al.  Prevalence  of  prostate  cancer  on  autopsy:  cross-­‐‑sectional  study  on  444 
unscreened  Caucasian  and  Asian  men.  J  Natl  Cancer  Inst  2013,  105:  1050-­‐‑1058.  445 
5.   American  Cancer   Society:  Cancer   Facts   and   Figures   2012.  Atlanta,  Ga:  American  Cancer   Society,   2012.  446 
Available   from.  447 
https://www.cancer.org/content/dam/cancer-­‐‑org/research/cancer-­‐‑facts-­‐‑and-­‐‑statistics/annual-­‐‑cancer-­‐‑facts-­‐‑448 
and-­‐‑figures/2012/estimated-­‐‑number-­‐‑of-­‐‑new-­‐‑cancer-­‐‑cases-­‐‑and-­‐‑deaths-­‐‑by-­‐‑sex-­‐‑2012.pdf   [Accessed   19th  449 
August  2018]  450 
6.   The   National   Cancer   Registration  Service,   Eastern   Office  [Internet]   Available  451 
from  http://www.ncras.nhs.uk/ncrs-­‐‑east/  [Accessed  14th  August  2018]  452 
7.   Zelefsky  MJ,  Eastham  JA,  Sartor  AO:  Cancer  of   the  prostate.   In:  DeVita  VT  Jr,  Lawrence  TS,  Rosenberg  453 
SA:  Cancer:  Principles  and  Practice  of  Oncology.  9th  ed.  Philadelphia,  Pa:  Lippincott  Williams  &  Wilkins,  454 
2011,  pp.  1220-­‐‑7121.  455 
8.   PDQ  Adult  Treatment  Editorial  Board.  Prostate  Cancer  Treatment  (PDQ®):  Patient  Version.  2018  Apr  30.  456 
In:   PDQ   Cancer   Information   Summaries   [Internet].   Bethesda   (MD):   National   Cancer   Institute   (US);  457 
2002-­‐‑.  Available  from:  https://www.ncbi.nlm.nih.gov/books/NBK65915/  [Accessed  19th  August  2018]  458 
9.   Hamdy  FC,  Donovan  JL,  Lane  JA,  et  al.  10-­‐‑Year  Outcomes  after  Monitoring,  Surgery,  or  Radiotherapy  for  459 
Localized  Prostate  Cancer.  N  Engl  J  Med  2016,  375:  1415-­‐‑1424.  460 
10.   Graham   J,   Kirkbride   P,   Cann   K,  Hasler   E,   Prettyjohns   M.   Prostate   cancer:summary   of   updated  NICE  461 
guidance.  BMJ  2014,  8;348:f7524.  doi:10.1136/bmj.f7524.  462 
11.   Ragde  H,   Blasko   JC,  Grimm  PD,   et   al.   Interstitial   iodine-­‐‑125   radiation  without   adjuvant   therapy   in   the  463 
treatment  of  clinically  localized  prostate  carcinoma.  Cancer  1997,  80:  442-­‐‑453.  464 
12.   Immediate   versus   deferred   treatment   for   advanced   prostatic   cancer:   initial   results   of   the   Medical  465 
Research   Council   Trial.   The   Medical   Research   Council   Prostate   Cancer   Working   Party   Investigators  466 
Group.  Br  J  Urol  1997,  79:  235-­‐‑426.    467 
Int.  J.  Mol.  Sci.  2019,  20,  x  FOR  PEER  REVIEW   13   of   17  
 
13.   James  ND,  de  Bono   JS,   Spears  MR,   et  al.  Abiraterone   for   Prostate  Cancer  Not  Previously  Treated  with  468 
Hormone  Therapy.  N  Engl  J  Med  2017,  377:  338-­‐‑351.  469 
14.   Dearnaley  DP,  Mason  MD,  Parmar  MK,  et  al.:  Adjuvant  therapy  with  oral  sodium  clodronate  in  locally  470 
advanced   and   metastatic   prostate   cancer:   long-­‐‑term   overall   survival   results   from   the   MRC   PR04   and  471 
PR05  randomised  controlled  trials.  Lancet  Oncol  2009,  10:  872-­‐‑876.    472 
15.   H.I.  Scher,  K.  Fizazi,  F.  Saad,  M.E.  Taplin,  C.N.  Sternberg,  K.  Miller,  et   al.   Increased   survival   with  473 
enzalutamide  in  prostate  cancer  after  chemotherapy  N  Engl  J  Med  2012,  367:  1187-­‐‑1197.  474 
16.   Kantoff   PW,  Higano  CS,  Shore  ND,   et   al.   Sipuleucel-­‐‑T   immunotherapy   for   castration-­‐‑resistant   prostate  475 
cancer.  N  Engl  J  Med  2010,  363:  411-­‐‑422.  476 
17.   Parker  C,  Nilsson  S,  Heinrich  D,  Helle  SI,  O’Sullivan  JM,  Fossa  SD,  et  al.  Alpha  emitter  radium-­‐‑223  and  477 
survival  in  metastatic  prostate  cancer.  N  Engl  J  Med.  2013,  369:  213–23.  doi:  10.1056/NEJMoa1213755.  478 
18.   J.S.  de   Bono,  S.  Oudard,  M.  Ozguroglu,  S.Hansen,  J.P.  Machiels,  I.  Kocak   Prednisone   plus   cabazitaxel   or  479 
mitoxantrone  for  metastatic   castration-­‐‑resistant  prostate   cancer  progressing  after  docetaxel   treatment:  a  480 
randomised  open-­‐‑label  trial.  Lancet,  2010,  376  :  1147-­‐‑1154.  481 
  482 
19.   Fizazi  K,  Carducci  M,  Smith  M,  et  al.  Denosumab  versus  zoledronic  acid  for  treatment  of  bone  metastases  483 
in   men   with   castration-­‐‑resistant   prostate   cancer:   a   randomised,   double-­‐‑blind   study.   Lancet   2011,   377:  484 
813-­‐‑822.  485 
20.   Oosterhof   GO,   Roberts   JT,   de   Reijke   TM,   et   al.   Strontium   (89)   chloride   versus   palliative   local   field  486 
radiotherapy   in   patients   with   hormonal   escaped   prostate   cancer:   a   phase   III   study   of   the   European  487 
Organisation  for  Research  and  Treatment  of  Cancer,  Genitourinary  Group.  Eur  Urol  2003,  44:  519-­‐‑26.  488 
21.   Fizazi  K,  Tran  N,  Fein  L,   et  al.  Abiraterone  plus  Prednisone   in  Metastatic,  Castration-­‐‑Sensitive  Prostate  489 
Cancer.  N  Engl  J  Med  2017,  377:  352-­‐‑360.  490 
22.   Rajabi  M,  Mousa  SA.  The  Role  of  Angiogenesis  in  Cancer  Treatment.  Biomedicines  2017,  21;5(2).pii:E34.  491 
23.   Winkler   F.  Hostile   takeover:   how   tumours  hijack  pre-­‐‑existing  vascular   environments   to   thrive.   J  Pathol  492 
2017,  242:  267-­‐‑272.  493 
24.   Hanahan  D,  Weinberg  RA.  Hallmarks  of  Cancer:  The  Next  Generation.  Cell  2011,  144:  646  –  674.  494 
25.   Pavlakovic   H,   Havers   W,   Schweigerer   L.   Multiple   angiogenesis   stimulators   in   a   single   malignancy:  495 
Implications  for  anti-­‐‑angiogenic  tumour  therapy.  Angiogenesis  2001,  4:  259–262.  496 
26.   Kerbel,  R.S.  Tumor  angiogenesis.  N  Engl  J  Med  2008,  358:  2039–2049  497 
27.   Gressett   M,   Shah   SR   Intricacies   of   bevacizumab-­‐‑induced   toxicities   and   their   management.   Ann  498 
Pharmacother  2009,  43:  490–501  499 
28.   Kamba  T,  McDonald  D.M.  Mechanisms   of   adverse   effects  of  anti-­‐‑VEGF   therapy   for   cancer.  Br  J  Cancer  500 
2007,  96:  1788–1795.  501 
29.   Ferrara  N.  VEGF  as  a  therapeutic  target  in  cancer.  Oncology  2005,  69(Suppl.  3):  11–16.     502 
30.   Carmeliet  P,  Jain  RK.  Molecular  mechanisms  and  clinical  applications  of  angiogenesis.  Nature  2011,  473:  503 
298–307.  504 
31.   El-­‐‑Kenawi  AE,   El-­‐‑Remessy  AB.  Angiogenesis   inhibitors   in   cancer   therapy:  Mechanistic   perspective   on  505 
classification  and  treatment  rationales.  Br  J  Pharmacol  2013,  170:  712–729.  506 
32.   Mundel  TM,  Kalluri  R.  Type  IV  collagen-­‐‑derived  angiogenesis  inhibitors.  Microvasc  Res  2007,  74:  85–89.  507 
33.   Kurozumi  K,  Ichikawa  T,  Onishi  M,  Fujii  K,  Date  I.  Cilengitide  treatment  for  malignant  glioma:  current  508 
status  and  future  direction.  Neurol  Med  Chir  (Tokyo)  2012,  52:  539-­‐‑547.     509 
34.   Su  J,  Cai  M,  Li  W,  et  al.  Molecularly  Targeted  Drugs  Plus  Radiotherapy  and  Temozolomide  Treatment  for  510 
Newly  Diagnosed  Glioblastoma:  A  Meta-­‐‑Analysis  and  Systematic  Review.  Oncol  Res  2016,  24:  117-­‐‑28.  511 
35.   Herbert   SP,   Stainier,   DY.   Molecular   control   of   endothelial   cell   behaviour   during   blood   vessel  512 
morphogenesis.  Nat  Rev  Mol  Cell  Biol  2011,  12:  551–564.  513 
36.   Margolin   K,   Gordon   SM,   Holmgren   E   et   al.   Phase   Ib   trial   of   intravenous   recombinant   humanized  514 
monoclonal  antibody  to  vascular  endothelial  growth  factor  in  combination  with  chemotherapy  in  patients  515 
with  advanced  cancer:  pharmacologic  and  long-­‐‑term  safety  data.  J  Clin  Oncol  2011,  19:  851–856.  516 
37.   Ferrara   N,   Adamis   AP.   Ten   years   of   anti-­‐‑vascular   endothelial   growth   factor   therapy.  Nat   Rev   Drug  517 
Discovery  2016,  15:  385-­‐‑403.  518 
38.   Li   M,   Kroetz   DL.   Bevacizumab-­‐‑induced   hypertension:   Clinical   presentation   and   molecular  519 
understanding.  Pharmacol  Ther  2018,  182:  152-­‐‑160.  520 
Int.  J.  Mol.  Sci.  2019,  20,  x  FOR  PEER  REVIEW   14   of   17  
 
39.   Minder  P,  Zajac  E,  Quigley  JP,  Deryugina  EI.  EGFR  Regulates  the  Development  and  Microarchitecture  of  521 
Intratumoral   Angiogenic   Vasculature   Capable   of   Sustaining   Cancer   Cell   Intravasation.  Neoplasia   (New  522 
York,  NY)  2015,  17:  634-­‐‑649.     523 
40.   Sharma  S,  Sharma  MC,  Sarkar  C.  Morphology  of  angiogenesis  in  human  cancer:  a  conceptual  overview,  524 
histoprognostic  perspective  and  significance  of  neoangiogenesis.  Histopathology  2005,  46:  481-­‐‑489.  525 
41.   Bono   AV,   Celato   N,   Cova   V,   Salvadore   M,   Chinetti   S,   Novario   R.   Microvessel   density   in   prostate  526 
carcinoma.  Prostate  Cancer  Prostatic  Dis  2002,  5:  123-­‐‑127.  527 
42.   Borre  M,  Offersen  BV,  Nerstrom  B,  Overgaard  J.  Microvessel  density  predicts  survival  in  prostate  cancer  528 
patients  subjected  to  watchful  waiting  Br  J  Cancer  1998,  78:  940-­‐‑944  529 
43.   Jiang   J,   Chen   Y,   Zhu   Y,   Yao   X,   Qi   J.   Contrast-­‐‑enhanced   ultrasonography   for   the   detection   and  530 
characterization   of  prostate   cancer:   correlation  with  microvessel   density   and  Gleason   score.  Clin  Radiol  531 
2011,  66:  732–737.  532 
44.   Tretiakova  M,  Antic   T,   Binder   D,  Kocherginsky  M,   Liao  C,   Taxy   JB,   Oto  A.Microvessel   density   is   not  533 
increased  in  prostate  cancer:  digital  imaging  of  routine  sections  and  tissue  microarrays.  Hum  Pathol  2013,  534 
44:  495-­‐‑502.  535 
45.   Miyata  Y  and  Saka,  H.  Reconsideration  of  the  clinical  and  histopathological  significance  of  angiogenesis  536 
in   prostate   cancer:  Usefulness   and   limitations   of  microvessel   density  measurement.   Int  J  Urol  2015,  22:  537 
806-­‐‑815.  doi:10.1111/iju.12840  538 
46.   Taverna  G,  Grizzi  F,  Colombo  P,  et  al.  Two-­‐‑dimensional  neovascular  complexity  is  significantly  higher  in  539 
nontumor   prostate   tissue   than   in   low-­‐‑risk   prostate   cancer.   Korean   J   Urol   2015,   56:   435–442.  540 
doi:10.4111/kju.2015.56.6.435  541 
47.   Taverna  G,  Grizzi  F,  Colombo  P,  Graziotti  P.  Is  angiogenesis  a  hallmark  of  prostate  cancer?.  Front  Oncol  542 
2013;  3:15.  doi:10.3389/fonc.2013.00015  543 
48.   de   Brot   S,   Ntekim  A,   Cardenas   R,   et   al.   Regulation   of   vascular   endothelial   growth   factor   in   prostate  544 
cancer.  Endocr  Relat  Cancer  2015,  22:  R107-­‐‑123.  545 
49.   Wong  SY,  Haack  H,  Crowley  D,  et   al.  Tumor-­‐‑secreted  vascular   endothelial   growth   factor-­‐‑C   is   necessary  546 
for   prostate   cancer   lymphangiogenesis,   but   lymphangiogenesis   is   unnecessary   for   lymph   node  547 
metastasis.  Cancer  Research  2005,  65:  9789–9798.     548 
50.   Wegiel  B,  Bjartell  A,  Ekberg  J,  Gadaleanu  V,  Brunhoff  C,  Persson  JL.  A  role  for  cyclin  A1  in  mediating  the  549 
autocrine   expression   of   vascular   endothelial   growth   factor   in   prostate   cancer.  Oncogene   2005,   24:  6385–550 
6393.     551 
51.   Green  MM,  Hiley  CT,  Shanks  JH,  et  al.  Expression  of  vascular  endothelial  growth  factor  (VEGF)  in  locally  552 
invasive   prostate   cancer   is   prognostic   for   radiotherapy   outcome.   International   Journal   of   Radiation  553 
Oncology,  Biology,  Physics  2007,  67:  84–90.  554 
52.   Duque  JL,  Loughlin  KR,  Adam  RM,  Kantoff  PW,  Zurakowski  D,     Freeman  MR  Plasma   levels   of   vascular  555 
endothelial  growth  factor  are  increased  in  patients  with  metastatic  prostate  cancer.  Urology  1999,  54:  523–556 
527.  557 
53.   Hrouda  D,  Nicol  DL,  Gardiner  RA.  The   role   of   angiogenesis   in   prostate   development   and   the  558 
pathogenesis  of  prostate  cancer.  Urological  Research  2003,  30:  347–355.  559 
54.   McKay  RR,  Zurita  AJ,  Werner  L,  et  al.  Randomized  Phase  II  Trial  of  Short-­‐‑Course  Androgen  Deprivation  560 
Therapy  With   or  Without   Bevacizumab   for   Patients  With   Recurrent   Prostate   Cancer   After   Definitive  561 
Local  Therapy.  J  Clin  Oncol  2016,  34:  1913-­‐‑1920.  562 
55.   Kelly   WK,   Halabi   S,   Carducci   M,   et   al.   Randomized,   double-­‐‑blind,placebo-­‐‑controlled   phase   III   trial  563 
comparing   docetaxel   and   prednisone   with   or   without   bevacizumab   in   men   with   metastatic  564 
castration-­‐‑resistant  prostate  cancer:  CALGB  90401.  J  Clin  Oncol  2012,  30:  1534-­‐‑1540.  565 
56.   Tannock  IF,   Fizazi  K,  Ivanov  S,  et   al.     Aflibercept   versus   placebo   in   combination   with   docetaxel   and  566 
prednisone  for  treatment  of  men  with  metastatic  castration-­‐‑resistant  prostate  cancer  (VENICE):  a  phase  3,  567 
double-­‐‑blind  randomised  trial.  Lancet  Oncology  2013,  14:  760–768.    568 
57.   Michaelson  MD,  Oudard  S,  Ou  YC,  et  al.  Randomized,placebo-­‐‑controlled,  phase  III  trial  of  sunitinib  plus  569 
prednisone  versus  prednisone  alone  in  progressive,  metastatic,  castration-­‐‑resistant  prostate  cancer.  J  Clin  570 
Oncol  2014,  32:  76-­‐‑82.  571 
58.   Mangoni  M,  Vozenin  MC,  Biti  G,  Deutsch  E  Normal   tissues   toxicities   triggered   by   combined  572 
anti-­‐‑angiogenic  and  radiation   therapies:  hurdles  might  be  ahead.  British  Journal  of  Cancer  2012,  107:  308–573 
314.  574 
Int.  J.  Mol.  Sci.  2019,  20,  x  FOR  PEER  REVIEW   15   of   17  
 
59.   Ogita  S,  Tejwani  S,  Heilbrun  L,  et  al.  Pilot  Phase  II  Trial  of  Bevacizumab  Monotherapy  in  Nonmetastatic  575 
Castrate-­‐‑Resistant  Prostate  Cancer.  ISRN  Oncology  2012,  2012:  242850.  576 
60.   Ribatti  D,  Vacca  A.  New  Insights  in  Anti-­‐‑Angiogenesis  in  Multiple  Myeloma.  Int  J  Mol  Sci  2018,  19.  Pii:  577 
E2031.  578 
61.   Keizman  D,  Zahurak  M,  Sinibaldi  V,  et  al.  Lenalidomide  in  nonmetastatic  biochemically  relapsed  prostate  579 
cancer:  results  of  a  phase  I/II  double-­‐‑blinded,  randomized  study.  Clinical  Cancer  Research  2010,  16:  5269–580 
5276.  581 
62.   Petrylak  DP,  Vogelzang  NJ,  Budnik  N,  et  al.  Docetaxel  and  prednisone  with  or  without  lenalidomide  in  582 
chemotherapy-­‐‑naivepatients   with   metastatic   castration-­‐‑resistant   prostate   cancer   (MAINSAIL):  583 
arandomised,  double-­‐‑blind,  placebo-­‐‑controlled  phase  3  trial.  Lancet  Oncol  2015,  16:  417-­‐‑425.  584 
63.   Liu  ZQ,  Fang  JM,  Xiao  YY,  et  al.  Prognostic  role  of  vascular  endothelial  growth  factor  in  prostate  cancer:  a  585 
systematic  review  and  meta-­‐‑analysis.  Int  J  Clin  Exp  Med.  2015,  8:  2289–2298.  586 
64.   Wang  K,  Peng  HL,  Li  LK.  Prognostic  value  of  vascular  endothelial  growth  factorexpression   in  patients  587 
with  prostate  cancer:  a  systematic  review  withmeta-­‐‑analysis.  Asian  Pac  J  Cancer  Prev.  2012,  13:  5665-­‐‑9.  588 
65.   Scholz  A,  Harter  PN,  Cremer,  S,   et  al..  Endothelial   cell-­‐‑derived  angiopoietin-­‐‑2   is  a   therapeutic   target   in  589 
treatment-­‐‑naive  and  bevacizumab-­‐‑resistant  glioblastoma.  EMBO  Mol  Med  2016,  8:  39–57.  590 
66.   Lindholm   EM,   Krohn   M,   Iadevaia   S,   et   al.   Proteomic   characterization   of   breast   cancer   xenografts  591 
identifies  early  and   late  bevacizumab-­‐‑induced  responses  and  predicts  effective  drug  combinations.  Clin  592 
Cancer  Res  2014,  20:  404–412.    593 
67.   Madan   RA,   Karzai   FH,   Ning   YM,   et   al.   Phase   II   trial   of   docetaxel,   bevacizumab,   lenalidomide   and  594 
prednisone  in  patients  with  metastatic  castration-­‐‑resistant  prostate  cancer.  BJU  Int  2016,  118:  590-­‐‑597.  595 
68.   Brauer,  M.  J.  et  al.  Identification  and  analysis  of  in  vivo  VEGF  downstream  markers  link  VEGF  pathway  596 
activity  with  efficacy  of  anti-­‐‑VEGF  therapies.  Clin  Cancer  Res  2013,  19:  3681–3692.  597 
69.   de  Haas,  S.  et  al.  Genetic  variability  of  VEGF  pathway  genes  in  six  randomized  Phase  III  trials  assessing  598 
the  addition  of  bevacizumab  to  standard  therapy.  Angiogenesis.  2014,  17:  909–920.  599 
70.   Makhov   PB,   Golovine   K,   Kutikov   A,   et   al.   Modulation   of   Akt/mTOR   signalling   overcomes   sunitinib  600 
resistance  in  renal  and  prostate  cancer  cells.  Molecular  Cancer  Therapeutics  2012,  11:  1510–1517.  601 
71.   Carver  BS,  Chapinski  C,  Wongvipat  J,  et  al.Reciprocal  feedback  regulation  of  PI3K  and  androgen  receptor  602 
signaling  in  PTEN-­‐‑deficient  prostate  cancer.  Cancer  Cell  2011,  19:      575-­‐‑86.  doi:10.1016/j.ccr.2011.04.008.  603 
72.   Wang  Y,  Kreisberg  JI,  Ghosh  PM.  Cross-­‐‑talk  between  the  androgen  receptor  and  the  phosphatidylinositol  604 
3-­‐‑kinase/Akt  pathway  in  prostate  cancer.  Curr  Cancer  Drug  Targets  2007,  7:      591-­‐‑604.  605 
73.   Yamamoto  Y,  De  Velasco  MA,  Kura  Y,   et  al.  Evaluation   of   in  vivo   responses  of   sorafenib   therapy   in   a  606 
preclinical  mouse  model  of  PTEN-­‐‑deficient  of  prostate  cancer.  J  Transl  Med  2015,  13:  150.  607 
74.   De   Velasco   MA,   Kura   Y,   Yoshikawa   K,   Nishio   K,   Davies   BR,   Uemura   H.   Efficacy   of   targeted   AKT  608 
inhibition  in  genetically  engineered  mouse  models  of  PTEN-­‐‑deficient  prostate  cancer.  Oncotarget  2016,  7:  609 
15959-­‐‑15976.  610 
75.   Sordello,   S.;   Bertrand,  N.;   Plouet,   J.   Vascular   endothelial   growth   factor   is   up-­‐‑regulated   in   vitro   and   in  611 
vivo  by  androgens.  Biochem.  Biophys.  Res.  Commun  1998,  251:  287–290.  612 
76.   Eisermann   K,   Fraizer   G.   The   Androgen   Receptor   and   VEGF:   Mechanisms   of   Androgen-­‐‑Regulated  613 
Angiogenesis  in  Prostate  Cancer.  Cancers  (Basel).  2017  9.  pii:  E32.  doi:  10.3390/cancers9040032.  614 
77.   Kashyap,   V.;   Ahmad,   S.;   Nilsson,   E.M.;   Helczynski,   L.;   Kenna,   S.;   Persson,   J.L.;   Gudas,   L.J.;   Mongan,  615 
N.P.The   lysine   specific   demethylase-­‐‑1   (LSD1/KDM1A)   regulates   VEGF-­‐‑A   expression   in   prostate  616 
cancer.Mol  Oncol  2013,  7,  555–566.  617 
78.   Deng,   X.;   Shao,   G.;   Zhang,   H.;   Li,   C.;   Zhang,   D.;   Cheng,   L.;   Elzey,   B.;   Pili,   R.;   Ratliff,   T.;   Huang,   J.  618 
Proteinarginine   methyltransferase   5   functions   as   an   epigenetic   activator   of   the   androgen   receptor   to  619 
promote  prostate  cancer  cell  growth.  Oncogene  2016,  36,  1223–1231.  620 
79.   Eisermann,  K.;  Broderick,  C.J.;  Bazarov,  A.;  Moazam,  M.M.;  Fraizer,  G.C.  Androgen  up-­‐‑regulates  vascular  621 
endothelial  growth  factor  expression  in  prostate  cancer  cells  via  an  Sp1  binding  site.  Mol  Cancer  2013,  12,  622 
7.  623 
80.   Antonarakis,   E.;   Armstrong,   A.;   Dehm,   S.;   Luo,   J.   Androgen   receptor   variant-­‐‑driven   prostate   cancer:  624 
Clinical  implications  and  therapeutic  targeting.  Prostate  Cancer  Prostatic  Dis.  2016,  19,  231–241.  625 
81.   Fernandez  EV,  Reece  KM,  Ley  AM,  et  al.  Dual  targeting  of  the  androgen  receptor  and  hypoxia-­‐‑inducible  626 
factor  1α      pathways  synergistically  inhibits  castration-­‐‑resistant  prostate  cancer  cells.  Mol  Pharmacol.  2015  627 
87:1006-­‐‑12.  doi:  10.1124/mol.114.097477.  628 
Int.  J.  Mol.  Sci.  2019,  20,  x  FOR  PEER  REVIEW   16   of   17  
 
82.   Pignon  JC,  Koopmansch  B,  Nolens  G,  Delacroix  L,  Waltregny  D,  Winkler  R.Androgen  receptor  controls  629 
EGFR   and   ERBB2   gene   expression   at   different   levels   in   prostate   cancer   cell   lines.   Cancer   Res.   2009,  630 
69:2941-­‐‑2949.  doi:10.1158/0008-­‐‑5472.  631 
83.   Zheng  Y,   Izumi  K,  Yao   JL,  Miyamoto  H.  Dihydrotestosterone  upregulates   the   expression  of   epidermal  632 
growth  factor  receptor  and  ERBB2  in  androgen  receptor-­‐‑positive  bladder  cancer  cells.  Endocr  Relat  Cancer.  633 
2011,  18:  451-­‐‑464.  doi:  10.1530/ERC-­‐‑11-­‐‑0010.  634 
84.   Tabernero   J.   The   role   of   VEGF   and   EGFR   inhibition:   implications   for   combining   anti-­‐‑VEGF   and  635 
anti-­‐‑EGFR  agents.  Mol  Cancer  Res.  2007,  5:203-­‐‑220.  636 
85.   Mabjeesh   NJ,   Willard   MT,   Frederickson   CE,   et   al.   Androgens   stimulate   hypoxia-­‐‑inducible   factor   1  637 
activation  via  autocrine   loop  of   tyrosine  kinase   receptor/phosphatidylinositol  3'ʹ-­‐‑kinase/protein  kinase  B  638 
in  prostate  cancer  cells.  Clin  Cancer  Res.  2003,  9:  2416–2425.  639 
86.   Shabsigh  A,  Ghafar  MA,  de  la  Taille  A,  et  al.  Biomarker  analysis  demonstrates  a  hypoxic  environment  in  640 
the  castrated  rat  ventral  prostate  gland.  J  Cell  Biochem.  2001,  81:437-­‐‑444.     641 
87.   Halin   S,   Hammarsten   P,   Wikström   P,   Bergh  A.   Androgen-­‐‑insensitive   prostate   cancer   cells   transiently  642 
respond  to  castration  treatment  when  growing  in  an  androgen-­‐‑dependent  prostate  environment.  Prostate.  643 
2007;  67:370-­‐‑377.  644 
88.   Mitani  T,  Harada  N,  Nakano  Y,  Inui  H,  Yamaji  R.  Coordinated  action  of  hypoxia-­‐‑inducible  factor-­‐‑1α  and  645 
β-­‐‑catenin  in  androgen  receptor  signaling.  J  Biol  Chem.  2012;  287:33594–33606.  doi:10.1074/jbc.M112.388298  646 
89.   Horii  K,  Suzuki  Y,  Kondo  Y,  et  al.  Androgen-­‐‑dependent  gene  expression  of  prostate-­‐‑specific  antigen   is  647 
enhanced  synergistically  by  hypoxia  in  human  prostate  cancer  cells.  Mol  Cancer  Res.  2007;  5:383-­‐‑391.  648 
90.   Cereda  V,  Formica  V,  Roselli  M.  Issues  and  promises  of  bevacizumab  in  prostate  cancer  treatment.  Expert  649 
Opin  Biol  Ther.  2018  Jun;18(6):707-­‐‑717.  doi:  10.1080/14712598.2018.1479737.  650 
91.   Bates   DO,   Cui   TG,   Doughty   JM,   et   al.   VEGF165b,   an   inhibitory   splice   variant   of   vascular   endothelial  651 
growth  factor,  is  down-­‐‑regulated  in  renal  cell  carcinoma.  Cancer  Res  2002,  62:  4123-­‐‑4131.  652 
92.   Woolard  J,  Wang  WY,  Bevan  HS,  et  al.VEGF165b,  an  inhibitory  vascular  endothelial  growth  factor  splice  653 
variant:  mechanism  of  action,  in  vivo  effect  on  angiogenesis  and  endogenous  protein  expression.  Cancer  654 
Research  2001,  64:  7822–7835.     655 
93.   Oltean  S,   Gammons  M,  Hulse  R,   et   al.  SRPK1   inhibition  in   vivo:   modulation   of   VEGF   splicing   and  656 
potential  treatment  for  multiple  diseases.  Biochemical  Society  Transactions  2012,  40:  831–835.     657 
94.   Auboeuf  D,  Dowhan  DH,  Kang  YK,  et   al/Differential   recruitment   of   nuclear   receptor   coactivators   may  658 
determine  alternative  RNA  splice  site  choice  in  target  genes.  PNAS  2004,  101:  2270–2274.    659 
95.   Peach  CJ,  Mignone  VW,  Arruda  MA,  et  al.  Molecular  Pharmacology  of  VEGF-­‐‑A  Isoforms:  Binding  and  660 
Signalling  at  VEGFR2.  International  Journal  of  Molecular  Sciences  2018,  19:  1264.  661 
96.   Amin  EM,  Oltean  S,  Hua  J,  et  al.  WT1  mutants  reveal  SRPK1  to  be  a  downstream  angiogenesis  target  by  662 
altering  VEGF  splicing.  Cancer  cell  2011,  20:  768-­‐‑780.     663 
97.   Nowak  DG,  Woolard  J,  Amin  EM,  et   al.     Expression   of   pro-­‐‑   and   anti-­‐‑angiogenic   isoforms   of   VEGF   is  664 
differentially  regulated  by  splicing  and  growth  factors.  Journal  of  Cell  Science  2008,  121:  3487–3495.     665 
98.   Nowak  DG,   Amin  EM,     Rennel  ES,      et   al.     Regulation   of   vascular   endothelial   growth   factor   (VEGF)  666 
splicing   from   pro-­‐‑angiogenic   to   anti-­‐‑angiogenic   isoforms:   a   novel   therapeutic   strategy   for  667 
angiogenesis.  Journal  of  Biological  Chemistry  2010,  285:  5532–5540.    668 
99.   Mavrou  A,  Brakspear  K,  Hamdollah-­‐‑Zadeh  M,  et  al.  Serine-­‐‑arginine  protein  kinase  1  (SRPK1)  inhibition  669 
as  a  potential  novel  targeted  therapeutic  strategy  in  prostate  cancer.  Oncogene  2015,  34:  4311-­‐‑4319.  670 
100.   Mavrou  A,   Oltean   S.   SRPK1   inhibition   in   prostate   cancer:   A   novel   anti-­‐‑angiogenic   treatment   through  671 
modulation  of  VEGF  alternative  splicing.  Pharmacol  Res  2016,  107:  276-­‐‑281.  672 
101.   Van   den   Brûle   FA,   Waltregny   D,   Castronovo   V,   et   al.   Increased   expression   of   galectin-­‐‑1   in  673 
carcinoma-­‐‑associated   stroma   predicts   poor   outcome   in   prostate   carcinoma   patients.   J   Pathol   2001,  674 
193:80-­‐‑87.  675 
102.   Stanley  P.  Galectin-­‐‑1  Pulls  the  Strings  on  VEGFR2.  Cell  2014,  156:625-­‐‑626  676 
103.   Jaworski   FM,   Gentilini   LD,   Gueron   G,   et   al.   In   Vivo   Hemin   Conditioning   Targets   the   Vascular   and  677 
Immunologic   Compartments   and   Restrains   Prostate   Tumor   Development.   Clin   Cancer   Res   2017,  678 
23:5135-­‐‑5148.  doi:10.1158/1078-­‐‑0432.CCR-­‐‑17-­‐‑0112.  679 
104.   Diego  J,  Laderach,  Lucas  D,  et  al   .A  Unique  Galectin  Signature   in  Human  Prostate  Cancer  Progression  680 
Suggests  Galectin-­‐‑1  as  a  Key  Target  for  Treatment  of  Advanced  Disease  Cancer  Res  2013,  73:  86-­‐‑96;  DOI:  681 
10.1158/0008-­‐‑5472.CAN-­‐‑12-­‐‑1260  682 
Int.  J.  Mol.  Sci.  2019,  20,  x  FOR  PEER  REVIEW   17   of   17  
 
105.   Goud  NS,  Soukya  PSL,  Ghouse  M,  Komal  D,  Alvala  R,  Alvala  M.  Human  Galectin-­‐‑1  683 





©  2019  by  the  authors.  Submitted  for  possible  open  access  publication  under  the  terms  
and   conditions   of   the   Creative   Commons   Attribution   [CC   BY]   license  
[http://creativecommons.org/licenses/by/4.0/].  
 688 
  689 
